Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
30 September 2022 - 12:24PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Board
Committee Changes
30 September 2022 10:30 BST
Remuneration Committee Chair Appointment
AstraZeneca PLC today announced the appointment of Sheri McCoy,
Non-Executive Director, as Chair of the Remuneration
Committee. Sheri has served as a member of the Remuneration
Committee since July 2018.
Sheri will succeed Michel Demaré who will step down as Chair
of the Remuneration Committee following his recent appointment as
Chair-designate of the Board. He will remain a member of the
Committee.
Sheri will also become a member of the Nomination and Governance
Committee.
These Remuneration Committee and Nomination and Governance
Committee changes are effective from 1 December 2022. As
previously announced, Michel Demaré will become Chair of the
Board at the end of the Company's Annual General Meeting in April
2023.
Notes
Biography and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
30 September 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Okt 2023 bis Nov 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Nov 2022 bis Nov 2023
